Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

LXRX | Lexicon Pharmaceuticals Inc

IndexRUT P/E- EPS (ttm)-0.68 Insider Own1.98% Shs Outstand244.93M Perf Week-16.24%
Market Cap240.03M Forward P/E- EPS next Y-0.76 Insider Trans- Shs Float240.09M Perf Month-42.01%
Income-130.72M PEG- EPS next Q-0.21 Inst Own77.34% Short Float / Ratio7.87% / 12.05 Perf Quarter-56.64%
Sales0.41M P/S585.44 EPS this Y-30.38% Inst Trans17.97% Short Interest18.90M Perf Half Y-60.16%
Book/sh0.76 P/B1.29 EPS next Y6.53% ROA-60.93% Target Price6.33 Perf Year-59.17%
Cash/sh1.05 P/C0.93 EPS next 5Y- ROE-101.65% 52W Range1.00 - 3.79 Perf YTD-48.69%
Dividend- P/FCF- EPS past 5Y12.05% ROI-44.98% 52W High-74.14% Beta1.19
Dividend %- Quick Ratio10.09 Sales past 5Y26.76% Gross Margin-16.42% 52W Low-2.00% ATR0.09
Employees135 Current Ratio10.10 Sales Q/Q805.71% Oper. Margin-31557.60% RSI (14)25.02 Volatility9.91% 7.52%
OptionableYes Debt/Eq0.57 EPS Q/Q-33.48% Profit Margin-32038.97% Rel Volume2.27 Prev Close1.02
ShortableYes LT Debt/Eq0.56 EarningsAug 03 AMC Payout- Avg Volume1.57M Price0.98
Recom2.00 SMA20-24.96% SMA50-38.93% SMA200-55.64% Volume991,733 Change-3.92%
Date Action Analyst Rating Change Price Target Change
Mar-07-23Initiated Jefferies Hold $3
Aug-12-22Initiated Piper Sandler Overweight $10
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Sep-28-23 09:00AM
Sep-26-23 09:00AM
Sep-20-23 12:28PM
Sep-14-23 09:40PM
Sep-07-23 04:30PM
09:00AM Loading…
Aug-21-23 09:00AM
Aug-17-23 09:56AM
Aug-08-23 09:00AM
Aug-04-23 09:12AM
Aug-03-23 05:15PM
Jul-28-23 04:01PM
06:52AM Loading…
Jun-30-23 06:52AM
Jun-27-23 06:46AM
Jun-23-23 08:45PM
Jun-20-23 08:00AM
Jun-15-23 05:00PM
Jun-06-23 04:01PM
Jun-05-23 04:01PM
Jun-04-23 07:00AM
Jun-02-23 09:21AM
Jun-01-23 11:35AM
May-31-23 04:01PM
May-26-23 04:25PM
04:05PM Loading…
May-22-23 07:33AM
May-11-23 06:50AM
May-10-23 04:30PM
May-04-23 10:05AM
May-03-23 11:45AM
May-02-23 04:00PM
Apr-28-23 04:00PM
Apr-22-23 08:15AM
Apr-21-23 09:00AM
Apr-17-23 04:00PM
Mar-06-23 06:00AM
Mar-04-23 12:00PM
Mar-03-23 07:07AM
Mar-02-23 04:00PM
Feb-28-23 05:00PM
Feb-20-23 08:00AM
Feb-01-23 07:56AM
Jan-06-23 04:05PM
Dec-29-22 06:52PM
Dec-22-22 09:22AM
Dec-21-22 04:30PM
Nov-28-22 08:00AM
Nov-15-22 10:00AM
Nov-14-22 04:03PM
Nov-12-22 07:28AM
Nov-11-22 08:58AM
Nov-09-22 04:01PM
Nov-08-22 08:58AM
Nov-06-22 05:29PM
Nov-05-22 10:35AM
Nov-04-22 08:58AM
Oct-31-22 08:59AM
Oct-24-22 08:59AM
Oct-02-22 01:00PM
Sep-20-22 08:59AM
Aug-22-22 04:05PM
Aug-05-22 04:59PM
Aug-02-22 04:01PM
Jul-29-22 08:00AM
Jul-28-22 07:00AM
Jul-27-22 04:01PM
Jun-29-22 04:01PM
Jun-06-22 02:16PM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-11-22 06:35AM
May-05-22 06:00AM
Apr-29-22 08:00AM
Apr-07-22 08:00AM
Apr-04-22 08:00AM
Apr-02-22 12:15PM
Mar-21-22 08:01AM
Mar-18-22 09:57AM
Mar-17-22 04:14PM
Mar-08-22 04:34AM
Mar-04-22 05:10AM
Mar-03-22 06:21PM
Feb-28-22 04:54PM
Feb-25-22 09:03PM
Jan-13-22 09:00AM
Jan-04-22 04:05PM
Jan-03-22 10:46AM
Dec-30-21 04:05PM
Nov-15-21 04:30PM
Nov-14-21 08:35AM
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WADE JEFFREY LPresident and CFOSep 14Buy1.3810,00013,800264,341Sep 14 05:05 PM
McDermott WendyVP, Human ResourcesAug 04Buy1.846,00011,04028,478Aug 07 04:13 PM
COATS LONNELChief Executive OfficerJun 29Buy2.1610,00021,600814,359Jun 29 04:13 PM
COATS LONNELChief Executive OfficerJun 26Buy2.1810,00021,792804,359Jun 26 04:04 PM
COATS LONNELChief Executive OfficerJun 23Buy2.5010,00024,950794,359Jun 26 04:04 PM
McDermott WendyVP, Human ResourcesJun 23Buy2.4310,00024,30022,478Jun 27 04:22 PM
COATS LONNELChief Executive OfficerJun 22Buy2.3140,00092,400784,359Jun 22 04:01 PM
WADE JEFFREY LPresident and CFOJun 20Buy2.3312,00028,000254,341Jun 20 04:10 PM
Artal International S.C.A.DirectorJun 05Buy2.6027,775,05072,215,13078,634,381Jun 05 04:46 PM
Swain Judith LDirectorMay 21Option Exercise0.009,302040,332May 22 04:07 PM
Palantoni FrankDirectorMay 21Option Exercise0.009,302040,332May 22 04:06 PM
SOBECKI CHRISTOPHER JDirectorMay 21Option Exercise0.009,3020159,023May 22 04:06 PM
NIES ALAN SDirectorMay 21Option Exercise0.009,302041,046May 22 04:05 PM
DEBBANE RAYMONDDirectorMay 21Option Exercise0.009,3020340,847May 22 04:03 PM
LEFKOWITZ ROBERT J MDDirectorMay 21Option Exercise0.009,302040,332May 22 04:04 PM
BARKER SAM LDirectorMay 21Option Exercise0.009,302079,617May 22 04:02 PM
Amouyal PhilippeDirectorMay 21Option Exercise0.009,302040,332May 22 04:01 PM